• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications do not work for many people suffering from depression. A customized treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into personalized micro-interventions that improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients with the highest probability of responding to specific treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from certain treatments. They use sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence and other digital tools. Two grants totaling more than $10 million will be used to determine biological and behavioral factors that predict response.

The majority of research conducted to the present has been focused on clinical and sociodemographic characteristics. These include demographics like gender, age, and education, and clinical characteristics like symptom severity and comorbidities, as well as biological markers.

While many of these variables can be predicted from the information in medical records, only a few studies have employed longitudinal data to determine the causes of mood among individuals. A few studies also consider the fact that moods can vary significantly between individuals. Therefore, it is crucial to create methods that allow the identification of individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can identify different patterns of behavior and emotions that vary between individuals.

The team also devised an algorithm for machine learning to create dynamic predictors for each person's mood for depression. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

The digital phenotype was associated with CAT-DI scores, which is a psychometrically validated scale for assessing severity of symptom. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1 yet it is often underdiagnosed and undertreated2. In addition the absence of effective interventions and stigmatization associated with depression disorders hinder many from seeking home treatment for depression.

To aid in the development of a personalized treatment, it is important to identify the factors that predict symptoms. However, the methods used to predict symptoms depend on the clinical interview which is unreliable and only detects a tiny number of features associated with depression.2

Using machine learning to combine continuous digital behavioral phenotypes captured by smartphone sensors and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, CAT-DI) along with other indicators of severity of symptoms can improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes can provide continuous, high-resolution measurements. They also capture a wide range of unique behaviors and activity patterns that are difficult to capture through interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA depression treatment In uk Grand Challenge. Participants were sent online for assistance or medical care according to the degree of their depression. Those with a score on the CAT-DI scale of 35 or 65 were given online support by the help of a coach. Those with a score 75 patients were referred to in-person psychotherapy.

Participants were asked a series questions at the beginning of the study about their demographics and psychosocial traits. The questions asked included education, age, sex and gender and financial status, marital status, whether they were divorced or not, the frequency of suicidal ideas, intent or attempts, and how often they drank. The CAT-DI was used to assess the severity of depression-related symptoms on a scale from 100 to. CAT-DI assessments were conducted each other week for participants who received online support and every week for those who received in-person treatment.

Predictors of Treatment Response

Research is focusing on personalization of natural treatment for anxiety and depression for depression. Many studies are aimed at identifying predictors, which will aid clinicians in identifying the most effective drugs for each person. Pharmacogenetics in particular uncovers genetic variations that affect how the body's metabolism reacts to drugs. This allows doctors to select drugs that are likely to be most effective for each patient, minimizing the time and effort required in trial-and-error treatments and avoiding side effects that might otherwise hinder the progress of the patient.

Another promising approach is to create prediction models combining the clinical data with neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, like whether a medication can help with symptoms or mood. These models can also be used to predict the response of a patient to a treatment they are currently receiving and help doctors maximize the effectiveness of treatment currently being administered.

A new generation uses machine learning techniques like algorithms for classification and supervised learning such as regularized logistic regression, and tree-based techniques to combine the effects of multiple variables and increase the accuracy of predictions. These models have proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and could become the norm in the future treatment.

In addition to the ML-based prediction models research into the mechanisms that cause depression continues. Recent findings suggest that seasonal depression treatment is related to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression and anxiety for depression will be based upon targeted therapies that restore normal function to these circuits.

Internet-based-based therapies can be an effective method to achieve this. They can provide an individualized and tailored experience for patients. One study found that a program on the internet was more effective than standard care in alleviating symptoms and ensuring the best quality of life for those with MDD. A controlled study that was randomized to a personalized treatment for depression revealed that a significant percentage of participants experienced sustained improvement as well as fewer side effects.

Predictors of adverse effects

In the treatment of depression one of the most difficult aspects is predicting and determining which antidepressant medications will have no or minimal negative side negative effects. Many patients are prescribed various drugs before they find a drug that is safe and effective. Pharmacogenetics provides an exciting new method for an effective and precise method of selecting antidepressant therapies.

Many predictors can be used to determine which antidepressant is best to prescribe, including gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. However, identifying the most reliable and accurate predictive factors for a specific treatment will probably require randomized controlled trials with considerably larger samples than those typically enrolled in clinical trials. This is because the identifying of interactions or moderators may be much more difficult in trials that only consider a single episode of treatment per patient instead of multiple sessions of treatment over a period of time.

In addition, predicting a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's subjective perception of the effectiveness and tolerability. At present, only a handful of easily identifiable sociodemographic variables and clinical variables are reliably related to response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression what is depression treatment in its beginning stages, and many challenges remain. It is crucial to have a clear understanding and definition of the genetic mechanisms that underlie depression, and a clear definition of a reliable indicator of the response to treatment. In addition, ethical issues like privacy and the responsible use of personal genetic information, must be carefully considered. Pharmacogenetics can eventually reduce stigma associated with treatments for mental illness and improve treatment outcomes. However, as with any other psychiatric treatment, careful consideration and implementation is necessary. In the moment, it's recommended to provide patients with a variety of medications for depression that are effective and encourage patients to openly talk with their doctor.